Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sep 20, 2021 at 9:00 AM EDT
Sep 9, 2021 at 3:30 PM EDT
Aug 4, 2021 at 5:00 PM EDT
Recent Press Releases